Síndrome dos Ovários Policísticos: uma revisão comparativa entre anticoncepcionais orais combinados, metformina e agonistas do receptor GLP-1
DOI:
https://doi.org/10.34119/bjhrv9n3-043Keywords:
Síndrome dos Ovários Policísticos, farmacoterapia, GLP-1 análogos, contraceptivos combinados com metforminaAbstract
A Síndrome dos Ovários Policísticos (SOP) é uma endocrinopatia frequente em mulheres em idade reprodutiva, caracterizada por hiperandrogenismo, disfunção ovulatória e alterações metabólicas. Sua fisiopatologia envolve desregulação do eixo hipotálamo-hipófise-ovário, resistência à insulina e produção aumentada de andrógenos ovarianos. Embora os anticoncepcionais orais combinados permaneçam como primeira linha de escolha no tratamento das manifestações hiperandrogênicas, seu impacto sobre parâmetros metabólicos é limitado, especialmente em pacientes com resistência insulínica e obesidade. Os agonistas do receptor do peptídeo-1 semelhante ao glucagon (GLP-1), como a liraglutida e a semaglutida, têm se mostrado eficaz na redução do peso corporal, melhora da sensibilidade à insulina e efeitos benéficos sobre os perfis hormonais, tornando-se uma alternativa promissora para mulheres com SOP. Deste modo, o objetivo deste estudo será realizar uma revisão bibliográfica sobre a eficácia dos tratamentos da SOP: anticoncepcionais orais combinados em uso isolado, anticoncepcionais orais combinados com uso de metformina e fármaco análogos ao GLP-1. Este trabalho é uma revisão bibliográfica realizada por meio de levantamento de artigos científicos do período de 2020 a 2025, na base de dados PubMed, utilizando os seguintes descritores: polycystic ovary syndrome and pharmacotherapy.
References
ABDEL-MABOUD, M. et al. The comparative effectiveness of 55 interventions in obese patients with polycystic ovary syndrome: a network meta-analysis of 101 randomized trials. PLoS ONE, v. 16, n. 7, p. e0254412, 2021. DOI: https://doi.org/10.1371/journal.pone.0254412.
BADER, S. et al. A systematic review of GLP-1 on anthropometrics, metabolic and endocrine parameters in patients with PCOS. Women’s Health, v. 20, p. 17455057241234530, 2024. DOI: https://doi.org/10.1177/17455057241234530.
BO, Y. et al. Comparative efficacy of pharmacological interventions on metabolic and hormonal outcomes in polycystic ovary syndrome: a network meta-analysis of randomized controlled trials. BMC Women’s Health, v. 25, n. 1, p. 64, 2025. DOI: https://doi.org/10.1186/s12905-025-03594-6.
ELKIND-HIRSCH, K. E. et al. Liraglutide 3 mg on weight, body composition, and hormonal and metabolic parameters in women with obesity and polycystic ovary syndrome: a randomized placebo-controlled-phase 3 study. Fertility and Sterility, v. 118, n. 2, p. 371-381, 2022. DOI: https://doi.org/10.1016/j.fertnstert.2022.04.027.
FORSLUND, M. et al. Combined oral contraceptive pill compared with no medical treatment in the management of polycystic ovary syndrome: A systematic review. Clinical Endocrinology, v. 99, n. 1, p. 79-91, 2023. DOI: https://doi.org/10.1111/cen.14913.
FRAISON, E. et al. Metformin versus the combined oral contraceptive pill for hirsutism, acne, and menstrual pattern in polycystic ovary syndrome. Cochrane Database of Systematic Reviews, v. 8, n. 8, p. CD005552, 2020. DOI: https://doi.org/10.1002/14651858.CD005552.pub3.
GARZIA, E. et al. Hyperandrogenism and menstrual imbalance are the best predictors of metformin response in PCOS patients. Reproductive Biology and Endocrinology, v. 20, n. 1, p. 6, 2022. DOI: Hyperandrogenism and menstrual imbalance are the best predictors of metformin response in PCOS patients | Reproductive Biology and Endocrinology.
LIN, S. et al. Efficacy and safety of GLP-1 receptor agonists on weight management and metabolic parameters in PCOS women: a meta-analysis of randomized controlled trials. Scientific Reports, v. 15, n. 1, p. 16512, 2025. DOI: https://doi.org/10.1038/s41598-025-99622-4.
LIU, Y. et al. Improvement of insulin sensitivity increases pregnancy rate in infertile PCOS women: a systemic review. Frontiers in Endocrinology, v. 12, p. 657889, 2021. DOI: https://doi.org/10.3389/fendo.2021.657889.
MA, R. L. et al. Short-term combined treatment with exenatide and metformin for overweight/obese women with polycystic ovary syndrome. Chinese Medical Journal, v. 134, n. 23, p. 2882-2889, 2021. DOI: https://doi.org/10.1097/CM9.0000000000001712.
MELIN, J. et al. Metformin and combined oral contraceptive pills in the management of polycystic ovary syndrome: a systematic review and meta-analysis. Journal of Clinical Endocrinology & Metabolism, v. 109, n. 2, p. e817-e836, 2024. DOI: https://doi.org/10.1210/clinem/dgad.
SRIDHARAN, K.; SIVARAMAKRISHNAN, G. Expanding therapeutic horizons: glucagon-like peptide-1 receptor agonists and sodium glucose transporter-2 inhibitors in polycystic ovarian syndrome: a comprehensive review including systematic review and network meta-analysis of randomized clinical trials. Diabetology & Metabolic Syndrome, v. 17, n. 1, p. 168, 2025. DOI: https://doi.org/10.1186/s13098-025-01730-8.
WEN, Q. et al. Short-term effect of beinaglutide combined with metformin versus metformin alone on weight loss and metabolic profiles in obese patients with polycystic ovary syndrome: a pilot randomized trial. Frontiers in Endocrinology, v. 14, p. 1156521, 2023. DOI: https://doi.org/10.3389/fendo.2023.1156521.
XING, C. et al. Effect of metformin versus metformin plus liraglutide on gonadal and metabolic profiles in overweight patients with polycystic ovary syndrome. Frontiers in Endocrinology, v. 13, p. 945609, 2022. DOI: https://doi.org/10.3389/fendo.2022.945609.
